Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene by Afonso, Ana et al.
Afonso et al. Malaria Journal 2010, 9:135
http://www.malariajournal.com/content/9/1/135
Open Access RESEARCH
BioMed  Central
© 2010 Afonso et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research Plasmodium chabaudi chabaudi malaria parasites 
can develop stable resistance to atovaquone with a 
mutation in the cytochrome b gene
Ana Afonso*3,4, Zoraima Neto1, Helena Castro2, Dinora Lopes1, Ana C Alves1, Ana M Tomás5 and Virgílio D  Rosário1
Abstract
Background: Plasmodium falciparum, has developed resistance to many of the drugs in use. The recommended 
treatment policy is now to use drug combinations. The atovaquone-proguanil (AP) drug combination, is one of the 
treatment and prophylaxis options. Atovaquone (ATQ) exerts its action by inhibiting plasmodial mitochondria electron 
transport at the level of the cytochrome bc1 complex. Plasmodium falciparum in vitro resistance to ATQ has been 
associated with specific point mutations in the region spanning codons 271-284 of the cytochrome b gene. ATQ -
resistant Plasmodium yoelii and Plasmodium berghei lines have been obtained and resistant lines have amino acid 
mutations in their CYT b protein sequences. Plasmodium chabaudi model for studying drug-responses and drug-
resistance selection is a very useful rodent malaria model but no ATQ resistant parasites have been reported so far. The 
aim of this study was to determine the ATQ sensitivity of the P. chabaudi clones, to select a resistant parasite line and to 
perform genotypic characterization of the cytb gene of these clones.
Methods: To select for ATQ resistance, Plasmodium. chabaudi chabaudi clones were exposed to gradually increasing 
concentrations of ATQ during several consecutive passages in mice. Plasmodium chabaudi cytb gene was amplified and 
sequenced.
Results: ATQ resistance was selected from the clone AS-3CQ. In order to confirm whether an heritable genetic 
mutation underlies the response of AS-ATQ to ATQ, the stability of the drug resistance phenotype in this clone was 
evaluated by measuring drug responses after (i) multiple blood passages in the absence of the drug, (ii) freeze/thawing 
of parasites in liquid nitrogen and (iii) transmission through a mosquito host, Anopheles stephensi. ATQ resistance 
phenotype of the drug-selected parasite clone kept unaltered. Therefore, ATQ resistance in clone AS-ATQ is genetically 
encoded. The Minimum Curative Dose of AS-ATQ showed a six-fold increase in MCD to ATQ relative to AS-3CQ.
Conclusions: A mutation was found on the P. chabaudi cytb gene from the AS-ATQ sample a substitution at the residue 
Tyr268 for an Asn, this mutation is homologous to the one found in P. falciparum isolates resistant to ATQ.
Background
Malaria is one of the most common infectious diseases in
the world and one of the greatest global public health
problems, causing serious illness in 100-200 million peo-
ple and estimated to kill two million people annually, with
highest mortality rates among pregnant women and
young children. A variety of drugs are available for ther-
apy and prophylaxis. However, Plasmodium falciparum,
the main malaria agent, has developed resistance to many
of the drugs in common use (such as chloroquine and sul-
phadoxine) such that currently, drug combination ther-
apy using atemisinin derivatives is the recommended
treatment to prevent the appearance of multidrug-resis-
tant parasites. Thus, the spread of resistant parasites is a
serious health issue and new drugs are urgently needed.
The recommended treatment policy is now to use drug
combinations [1]. The atovaquone (ATQ) -proguanil
(AP) drug combination, distributed under the trade name
of Malarone®, is one of the treatment and prophylaxis
options. AP has a high cure rate, mild side effects [2], has
potent blood schizonticidal activity and is also effective
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against the pre-erythrocytic and sexual stages and proved
adequate in cases of multi-drug resistant P. falciparum
malaria [3,4]. ATQ exerts its action by inhibiting plasmo-
dial mitochondria electron transport at the level of the
cytochrome bc1 complex leading to collapse of the mito-
chondrial membrane potential [4-8] while proguanil (an
isopropylbiguanide) via its metabolite cycloguanil inhib-
its dihydrofolate reductase thus potenciating ATQ action
[4,9,10].
P. falciparum in vitro resistance to ATQ has been asso-
ciated with specific point mutations in the region span-
ning codons 271-284 of the cytochrome b gene (Pfcytb)
[7,11,12]. A high frequency of recrudescence was
observed in patients receiving ATQ, as a single drug ther-
apy against P. falciparum [13,14]. A Y268S point muta-
tion in the Pfcytb  gene, distinct from the mutations
observed in the lines selected in vitro for ATQ resistance,
was detected in the recrudescing parasites [7]. The poly-
morphism in codon 268 is used as marker for a molecular
surveillance of AP resistance [15-19]. AP treatment fail-
ures were increasingly reported a few years after its intro-
duction, with recrudescing parasites presenting a
markedly increased IC50 for ATQ [15,20,21]. In most
cases, recrudescence is associated with a mutant 268
codon, either Y268S [3,12,20,22-26], Y268N [15] or
Y268C mutation [21].
Along with the key issue of emergence and spreading of
polymorphisms conferring ATQ resistance, analysis of
Pfcytb field diversity presents an interest in population
genetics [27-31]. Indeed, the cytb gene is encoded by the
mitochondrial DNA and, as a consequence, is of unipa-
rental inheritance and under different evolution con-
straints compared to nuclear genes [32,33]. In particular,
interallelic recombination is not possible and polymor-
phisms, such as base substitutions or insertions, may
accumulate over time. In mammals, the cytb locus dis-
plays an approximately 10-fold higher mutation rate than
nuclear genes [34]. A rapid mutation rate (one mutation
in 105 parasites) was reported for Pfcytb [35], but 100-
1,000 lower rates were described subsequently [7].
A previous report showed that AP-resistant genotype
of P. falciparum can be detected in non-exposed areas.
Happi et al [36] found a Y268N mutation in P. falciparum
from Nigeria, where AP had not been used; this finding
suggests that the mutations in the cytb gene might occur
naturally.
ATQ-resistant Plasmodium yoelii and Plasmodium ber-
ghei lines have been derived from infected mice treated
with suboptimal doses of ATQ. All resistant lines have
single or double amino acid mutations in their CYT b
protein sequences [37,38], which were associated with
increased resistance to the collapsing of mitochondrial
membrane potentials and the inhibition of respiration
afforded by ATQ, though these mutations are in different
positions than the ones detected in resistant P. falci-
parum. Even though Plasmodium chabaudi is the most
useful rodent malaria model with respect to drug
responses, drug studies and drug resistance selection, no
ATQ (ATQ) resistant parasites have been reported so far.
The aim of this study was to determine the ATQ sensi-
tivity of the P. chabaudi clones, to select a resistant para-
site line and to perform genotypic characterization of the
cytb gene of these clones.
Methods
Parasites and hosts
Plasmodium chabaudi chabaudi clones were maintained
in 4-6 week old laboratory CD1 female mice, as described
by Walliker et al [39]. Mouse drinking water was supple-
mented with 0.05% paraminobenzoic acid (PABA).
The parasite clones used to select atovaquone (A TQ)
resistance were pyrimethamine and chloroquine resistant
mutants [40] derived from a cloned isolate, P. c. chabaudi
clone AS-3CQ (See Table S1, Additional file 1). Briefly,
the original AS isolate was cloned by limiting dilution
(AS-SENS), then selected for resistance to
pyrimethamine and recloned [41]. This clone, designated
AS-PYR, was later selected for resistance to chloroquine
and a line resistant to six daily doses of this drug at 3 mg
kg-1 was obtained [42]. This line was cloned and denoted
AS-3CQ. AS-3CQ was then subjected to further stepwise
increases of chloroquine, producing a line resistant to six
daily doses of chloroquine at 15 mg kg-1 [43]. This para-
site was cloned (AS-15CQ) and subjected to further
increments in chloroquine pressure to select parasites
that survived six daily doses of chloroquine at 30 mg kg-1
[40,42], which were cloned and termed AS-30CQ.
Pyrimethamine, chloroquine, mefloquine, artemisinin
and artesunate resistance in all parasites was shown to be
a stable phenotype after i) freeze/thawing, ii) serial blood
passages through mice in the absence of treatment, and
iii) transmission through mosquitoes [40-43].
Drug selection experiments
To select for ATQ resistance, P. c. chabaudi clones AS-
SENS, AS-PYR, AS-3CQ, AS-15CQ, AS-30CQ, AS-ATN
and AS-ART were exposed to gradually increasing con-
centrations of ATQ during several consecutive passages
in mice.
107 infected red blood cells were diluted in 0.2 ml of cit-
rate saline and inoculated intraperitoneally (i.p.), into
groups of ten mice. ATQ at the chosen doses were freshly
prepared in pure dimethylsulfoxide (DMSO) and admin-
istered orally three hours later. Blood smears were taken
every day from day 5 onwards and examined microscopi-
cally for parasites. Smears were fixed with methanol and
stained in 20% Giemsa for 20 minutes, after which slides
were washed and allowed to air-dry. Parasitaemia wasAfonso et al. Malaria Journal 2010, 9:135
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calculated as the percentage of infected red blood cells/
number of total red blood cells in 10 to 15 microscopic
fields. Parasites, which survived drug treatment, were
sub-inoculated into fresh mice and the treatment
repeated. In subsequent passages, drug concentrations
were gradually increased. To discard the possibility that
increases in drug tolerance were due to increased viru-
lence caused by multiple sub-inoculations, a parasite line
was maintained in parallel and passaged in untreated
mice the same number of times as the drug selected line.
Drug tests
In order to compare the drug responses of drug-selected
parasites to those of unselected controls at given time
points during the selection procedure, groups of 12 mice
were each inoculated i.p. with 107 parasites (day 0). For
this, ten mice were treated orally with drug at various
dosages, three hours after parasite inoculation on day 0;
the remaining two mice were given DMSO only. ATQ
solutions were freshly prepared in DMSO just prior to
administration. Blood smears were taken every day from
day 6 onwards, stained with Giemsa's stain, and examined
microscopically to determine the % parasitaemia in 10
microscopic fields.
Tests to evaluate the stability of drug-resistance
To assess whether ATQ resistance were a genetically sta-
ble feature, drug-resistant parasite clones were re-tested
for their drug responses after each of three different pro-
cedures: i) freeze-thaw cycles in liquid nitrogen, ii) ten
blood sub-inoculations in mice in the absence of drug
treatment and iii) transmission through mosquitoes.
Resistance quantification in the drug-selected parasite
clones was established in the following way. The mini-
mum curative dose (MCD) of each drug was first assessed
in drug-selected parasites and untreated control lines.
MCD was defined as the minimum dose of each drug that
would prevent re-appearance of parasites in all five mice
within each treated group at any time during the first 10
days of the follow-up period. A resistance index was
determined using the following equation:
DNA extraction
Parasitized red cells were harvested from mice under
general anaesthesia when trophozoite stages were most
prevalent, diluted into citrate saline (pH 7.2) and passed
through a column of fibrous cellulose powder twice
(CF11®, Whatman™) to remove mouse leukocytes [14].
The resulting RBC pellet was washed twice in PBS and
parasite DNA extracted by overnight incubation in lysis
solution (10 mM Tris [pH 8.0], 50 mM EDTA, 0.1%
sodium dodecyl sulfate [SDS], proteinase K [1 mg/ml]) at
42°C. After phenol extraction, DNA was precipitated
using propan-2-ol and ammonium acetate (3 M) and dis-
solved in TE buffer (10 mM Tris-Cl, 1 mM EDTA,
pH8.0). DNA samples were stored at -20°C.
Identification of the P. c. chabaudi cytb gene
The DNA sequences of the P. falciparum and P. yoelii cytb
gene were available online at the NCBI/NIH (National
Institute of Health) database [44]. To obtain the P. c. cha-
baudi  orthologues of this gene, these sequences were
retrieved and used in BLAST searches against the avail-
able  P. c. chabaudi sequences (shot gun clones and
genomic contigs), deposited at the P. c. chabaudi genome
database [45]. The sequences giving significant hits were
used to design P. c. chabaudi-specific oligonucleotide
primers to amplify overlapping DNA fragments spanning
the coding region, introns and both 5'- and 3'-non-coding
sequences (Table S2, Additional file 1). These were then
used in PCR amplifications containing P. c. chabaudi
genomic DNA templates, as described below.
Amplification and sequencing of the cytb gene of P. 
chabaudi
Genomic DNA was used as template in 50 μl PCR reac-
tions, containing 0.2 μM of each oligonucleotide primer,
1× PCR buffer (PromegaÔ), 2.5 mM MgCl2, 0.2 mM
dNTPs and 0.025 U/μl of Taq  DNA polymerase. PCR
products were purified using the QIAquickÒ PCR Purifi-
cation Kit from QIAGEN and sequenced using BigDye
chain termination v3.1 (Applied Biosystems). The
sequencing reactions were analysed by Macrogen®. The
primers used in sequencing reactions were those used for
the initial amplification of the fragments. Gene and pre-
dicted amino-acid sequences were manually compiled,
and then compared between drug selected and unse-
lected clones using an internet-based interface denoted
Multiple Sequence Alignment with hierarchical cluster-
ing [46], and default alignment parameters [47].
Results and Discussion
Selection of atovaquone (ATQ) resistant parasites
The  P. chabaudi parasite lines used were all derived
sequentially from a drug-sensitive cloned isolate denoted
AS-SENS (see Table S1, Additional file 1 for details).
These included: (i) a chloroquine sensitive,
pyrimethamine-resistant clone denoted AS-PYR, (ii) a
clone exhibiting low-level chloroquine-resistance
denoted AS-3CQ, (iii) a clone exhibiting intermediate-
level chloroquine-resistance denoted AS-15CQ, (iv) a
highly chloroquine-resistant clone denoted AS-30CQ, (v)
a clone exhibiting artesunate-resistance denoted AS-
ATN and (vi) a clone that is artemisinin-resistant denoted
AS-ART.
N fold resistance MCD drug selected parasites MCD drug uns −= /e elected parasitesAfonso et al. Malaria Journal 2010, 9:135
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In order to select P. chabaudi clones resistant to ATQ,
various parasite lines were subjected initially to sub-cura-
tive drug dose. Attempts to establish stable ATQ resis-
tance of the clones named AS-SENS, AS-PYR, AS-15CQ,
AS-30CQ, AS-ATN and AS-ART were unsuccessful.
ATQ resistance was only selected from the clone AS-
3CQ. Initial drug testing revealed that the maximum dose
of ATQ tolerated by ATQ sensitive parent parasites was
20 mg/kg/single dose. Parasites that survived that initial
dose were sub-inoculated and subjected to successive
increments in drug doses, as described in the Methods
section.
AS-3CQ parasite line responded well to the ATQ selec-
tion procedure described, and a line that tolerated a daily
dose of 120 mg/kg/day, was selected after nine passages.
At this stage, it was considered that a significant level of
resistance had been successfully achieved and thus the
ATQ treatment procedure was suspended.
Parasite lines containing populations of ATQ-resistant
parasites were subjected to cloning by limiting dilution.
Three clones were successfully established from the ATQ
resistant parasite population. Of these, one clone was
chosen on the basis of their faster growth rate and desig-
nated P. c. chabaudi AS-ATQ. AS-ATQ was tested for its
response to ATQ, immediately after cloning, and shown
to retain the same phenotype as that of the drug-resistant
population from which they had been derived. These par-
asites were then used in subsequent studies to further
investigate whether the observed drug resistance was sta-
ble.
ATQ resistance in P. chabaudi AS-ATQ is stable
In order to confirm whether an heritable genetic muta-
tion underlies the response of AS-ATQ to ATQ, the sta-
bility of the drug resistance phenotype in this clone was
evaluated by measuring drug responses after (i) multiple
blood passages in the absence of the drug, (ii) freeze/
thawing of parasites in liquid nitrogen and (iii) transmis-
sion through a mosquito host, Anopheles stephensi.
AS-ATQ parasite line was therefore subjected to 10 fur-
ther passages in untreated mice, after which it was tested
for its drug response, it was also deep-frozen in liquid
nitrogen, thawed after one week and inoculated back into
mice and mice infected with AS-ATQ were used to feed
A. stephensi mosquitoes which then were used to infect
mosquitoes again once the parasite cycle was completed,
and tested again for ATQ tolerance. It was observed that,
a ft e r:  a)  t hr ee  cyc les o f  fr ee zing  a nd t ha wing  in li quid
nitrogen, b) ten blood sub-inoculations in mice in the
absence of drug treatment and c) transmission through
mosquitoes, the AS-ATQ line recrudesced on the same
day as the parasite line before the tests for drug stability.
Thus AS-ATQ resistance has a stable phenotype in the
absence of drug, suggesting that the drug resistant phe-
notype is genetically encoded. The Minimum Curative
Dose (MCD) of AS-ATQ was assessed in parallel to the
untreated control line, AS-3CQ. AS-ATQ showed a six-
fold increase in MCD to A TQ relative to AS-3CQ (See
Table S3, Additional file 1 for details).
In summary, ATQ resistance phenotypes of the drug-
selected parasite clones were unaltered after passage in
the absence of drug pressure, after freezing and thawing
and after transmission through laboratory mosquitoes.
Therefore, ATQ resistance in clone AS-ATQ is geneti-
cally encoded.
ATQ resistance in P. chabaudi is associated with a mutation 
in the pccytb gene
With the objective of investigating whether the P. cha-
baudi orthologue of Pfcytb gene played a role in resis-
tance to ATQ in P. chabaudi, therefore, P. chabaudi
specific database sequences were used to design oligonu-
cleotide primers to amplify this gene (See Table S2, Addi-
tional file 1 for details).
In order to identify possible point mutations in this
gene, in the ATQ-resistant parasites relative to AS-3CQ,
the nucleotide sequence of this gene in both sensitive and
resistant parasites was determined.
The comparisons of the Pccytb coding region between
all parasites (AS-SENS, AS-PYR, AS-3CQ, AS-15CQ,
AS-30CQ, AS-ART, AS-ATN and AS-ATQ parasites)
revealed no differences. A difference was found only on
the AS-ATQ sample in relation to its progenitor AS-3CQ,
a substitution at the residue Tyr268 for an Asn, this muta-
tion is the homologous of the one found in P. falciparum
isolates resistant to ATQ [37].
Conclusions
Overall, the available data indicate that it is possible to
select atovaquone (ATQ) resistance using Plasmodium
chabaudi. ATQ resistance was obtained from a clone that
is resistant to pyrimethamine and presents a low resistant
phenotype to chloroquine.
Although studies made directly on P. falciparum pro-
vide more information, this presents several limitations,
such as the requirement of working with chimpanzees or
humans as hosts for infection, a fact which poses serious
ethical problems, which can be circumvented by working
with animals models, which make easier the selection of
drug-resistant mutants and the identification of genes
involved in the resistance.
Of all the rodent malaria models the Plasmodium cha-
baudi model is the most appropriate for studies on the
genetics of drug resistance, as P. chabaudi is the rodent
malaria model that shows most biological similarity to P.
falciparum  because it preferentially parasitizes mature
erythrocytes and the schizogony is synchronous. In addi-
tion several clones of this species are already available,Afonso et al. Malaria Journal 2010, 9:135
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which have been selected for resistance to a variety of dif-
ferent drugs. These parasites present the ideal starting
material for identifying drug resistance genes since they
have been selected from cloned sensitive parasites. In this
way, the mutant parasites should have identical genetic
backgrounds to the starting sensitive forms except for the
genes determining resistance.
Having all this in mind our objective was to determine
the ATQ sensitivity of the P. chabaudi clones and thus to
select a resistant parasite line and also to perform geno-
typic characterization of the cytb gene of these clones.
The objective of selecting an ATQ drug resistant clone of
P. chabaudi of stable phenotype was fulfilled and this new
clone can in the future be use as a model for future stud-
ies on malaria combined therapy with ATQ being one of
the drugs in the combination.
The study presented here gives extra evidence of the
genetic similarities between P. chabaudi and  P. falci-
parum concerning the genetics of drug resistance, as the
mutation detected in the Pccyb gene from the AS-ATQ
resistant clone is the same as the most common mutation
detected in Pfcytb gene in P. falciparum.
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